Source: Pharmacy Times articles
The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
Recent Content
- FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
- FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
- FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
- Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
- The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
- Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
- Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
- What Should Patients with Multiple Myeloma Know After ASCO 2025?
- Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials
- Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease